Diuretics in Heart Failure

Diuretics in HF: The Basics - De-Puffing Power

• Primary Goal: Rapid symptomatic relief from fluid overload (congestion).
  • Reduces dyspnea, orthopnea, edema, JVD.
• Mechanism: Promote renal sodium ($Na^+$) & water excretion.
  • This ↓ plasma volume, ↓ preload, and ↓ pulmonary congestion.
• Clinical Use: Cornerstone for managing symptoms in acute & chronic HF.
• Crucial for "de-puffing" by removing excess body fluid.
• Generally no standalone mortality benefit (MRAs are an exception).

⭐ Diuretics offer the quickest relief of congestive symptoms in acute HF.

Loop Diuretics - Fluid Fighters

• MoA: Inhibit Na-K-2Cl cotransporter in thick ascending limb (TAL) of Loop of Henle. Most potent diuretics.
• Drugs: Furosemide, Torsemide, Bumetanide.
  • Ethacrynic acid: for sulfa allergy (⚠️ higher ototoxicity risk).
• Use in HF: Rapid symptomatic relief of fluid overload (e.g., pulmonary/peripheral edema), reduces preload.
  • IV for acute decompensation; oral for chronic management.
• Key Adverse Effects:
  • Hypokalemia (monitor K+!), hypomagnesemia, hypocalcemia.
  • Ototoxicity (dose-dependent, rapid IV admin).
  • Hyperuricemia, dehydration.
• Dosing (Furosemide example): Oral 20-80 mg daily; IV 20-40 mg initial dose.
• Resistance: Consider ↑ dose, IV infusion, or add thiazide (sequential blockade).

⭐ Loop diuretics are first-line for rapid symptomatic relief in acute decompensated heart failure (ADHF) with signs of fluid overload.

Thiazides & MRAs - Combo Kings

• Thiazides (e.g., Hydrochlorothiazide, Chlorthalidone, Metolazone)
  • Mechanism: Inhibit Na-Cl cotransporter in Distal Convoluted Tubule (DCT).
  • Role in HF:
    • Synergistic effect with loop diuretics (sequential nephron blockade) to overcome diuretic resistance.
    • Metolazone particularly useful in advanced HF or renal impairment.
  • Adverse Effects: Hypokalemia, hyponatremia, hyperuricemia, hyperglycemia.
• Mineralocorticoid Receptor Antagonists (MRAs) (e.g., Spironolactone, Eplerenone)
  • Mechanism: Aldosterone antagonists; K+-sparing diuretics. Act on principal cells of collecting duct.
  • Role in HFrEF:
    • Reduce mortality & morbidity (NYHA Class II-IV with LVEF ≤ 35%; or post-MI, LVEF ≤ 40% + HF symptoms/DM).
    • Decrease cardiac fibrosis & remodeling.
  • Adverse Effects: Hyperkalemia (monitor K+ & renal function). Spironolactone: gynecomastia. Eplerenone: more selective, fewer endocrine effects.

  ⭐ MRAs (Spironolactone, Eplerenone) are the only diuretics demonstrating mortality benefit in chronic HFrEF.

Diuretic Strategy & Resistance - The Flow Showdown

• Goal: Achieve euvolemia, relieve congestion. Monitor daily weight, I/O, electrolytes (K+, Mg2+), renal function.

• Initial: Loop diuretics (furosemide, torsemide). Titrate to response.

• Diuretic Resistance: Persistent congestion despite escalating loop diuretic doses (e.g., > 80-160 mg IV furosemide equivalent/day).

  • Causes: ↓Renal perfusion, nephron adaptation (distal hypertrophy), ↓oral absorption (gut edema).

• Overcoming Resistance:

  • Sequential Blockade: Add thiazide (e.g., metolazone 5-10 mg) 30 min before loop.
  • MRAs (spironolactone, eplerenone) also useful, esp. if hypokalemia.

⭐ In diuretic resistance, adding a thiazide like metolazone 30 minutes before a loop diuretic can significantly enhance natriuresis by blocking sequential sodium reabsorption sites.

High‑Yield Points - ⚡ Biggest Takeaways

• Loop diuretics (e.g., furosemide) are first-line for symptomatic relief of volume overload in acute & chronic HF.
• Mechanism: Inhibit Na-K-2Cl cotransporter in thick ascending limb.
• Aldosterone antagonists (spironolactone, eplerenone) reduce mortality in HFrEF (NYHA II-IV).
• Thiazides are used for mild HF or synergistically with loops for refractory edema.
• Key adverse effects: hypokalemia (loops/thiazides), hyperkalemia (K-sparing), ototoxicity (loops), azotemia.
• Manage diuretic resistance with combination therapy or dose escalation.